Literature DB >> 12867252

Effective strategies for long-term statin use.

Gregg C Fonarow1, Karol E Watson.   

Abstract

Long-term statin use achieves a significant reduction in mortality (24% to 42%) for patients with coronary artery disease (CAD) that is equal to or greater than that seen with other secondary prevention medications, including aspirin, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors. In patients with diabetes, the reduction in mortality exceeds that seen with tight glycemic control or any other treatment for diabetes. Several studies have found that almost all patients with atherosclerosis are considered candidates for statin treatment. The scientific evidence needed to revise the national guidelines has been provided by showing that initiation of statins before hospital discharge results in (1). a marked increase in long-term treatment rates, (2). improved long-term patient compliance, (3). more patients reaching levels of low-density lipoprotein (LDL) cholesterol <100 mg/dL, and (4). improved clinical outcome. Nonetheless, many studies in a variety of clinical settings have demonstrated that, regardless of the health care delivery system, an unacceptable number of patients with atherosclerosis are left untreated or undertreated with statin therapy. Applying hospital-based systems has been demonstrated to address the problems of underuse. The national guidelines now recommend that, in addition to diet and exercise counseling, lipid-lowering medications be initiated before hospital discharge for patients diagnosed with cardiovascular disease. Optimal use of statins and other cardioprotective medications in high-risk patients could save >83000 lives per year in the United States.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867252     DOI: 10.1016/s0002-9149(03)00506-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Authors:  Allison B Reiss; Elzbieta Wirkowski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Statin use and musculoskeletal pain among adults with and without arthritis.

Authors:  Catherine Buettner; Matthew J Rippberger; Julie K Smith; Suzanne G Leveille; Roger B Davis; Murray A Mittleman
Journal:  Am J Med       Date:  2012-02       Impact factor: 4.965

Review 3.  Coronary heart disease in young adults.

Authors:  Jessica B Rubin; William B Borden
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

Review 4.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

5.  Prevalence of musculoskeletal pain and statin use.

Authors:  Catherine Buettner; Roger B Davis; Suzanne G Leveille; Murray A Mittleman; Kenneth J Mukamal
Journal:  J Gen Intern Med       Date:  2008-05-01       Impact factor: 5.128

6.  AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.

Authors:  Stephen L Pinkosky; Sergey Filippov; Rai Ajit K Srivastava; Jeffrey C Hanselman; Cheryl D Bradshaw; Timothy R Hurley; Clay T Cramer; Mark A Spahr; Ashley F Brant; Jacob L Houghton; Chris Baker; Mark Naples; Khosrow Adeli; Roger S Newton
Journal:  J Lipid Res       Date:  2012-11-01       Impact factor: 5.922

Review 7.  LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase.

Authors:  Sergey Filippov; Stephen L Pinkosky; Roger S Newton
Journal:  Curr Opin Lipidol       Date:  2014-08       Impact factor: 4.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.